AaratPatelMD

Rheumatology • Richmond, VA

Lupus & Related, Myositis, Rheumatoid Arthritis & Related, Spondyloarthropathy

Physician

Join to view full profile

Dr. Patel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Patel's full profile

Already have an account?

Office
9600 Patterson Ave
Richmond, VA 23229
Phone+1 804-217-9601

Fax+1 804-217-9602

Summary

Adult and Pediatric Rheumatology in Richmond and Charlottesville.

Education & Training

Stony Brook Medicine/University HospitalResidency, Internal Medicine/Pediatrics, 2004 - 2008
Ross University School of MedicineClass of 2004

Certifications & Licensure

VA State Medical License 2012 - 2026
PA State Medical License 2008 - 2012
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Rheumatology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Publications & Presentations

PubMed

Yao syndrome in a child with C2 deficiency.
Samantha Cresoe-Ortiz, Geoffrey Hall, Rachel L Randell, Monica G Lawrence, Aarat Patel
The Journal of Allergy and Clinical Immunology. in Practice. 2024-11-01
1 citations
COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases: results from the COVAD study.
Laura Andreoli, Daniele Lini, Karen Schreiber, Ioannis Parodis, Parikshit Sen
Rheumatology. 2024-05-02
Characteristics and risk factors of COVID-19 breakthrough infections in Idiopathic Inflammatory Myopathies: Results from the COVAD study.
Leonardo Santos Hoff, R Naveen, Parikshit Sen, Jessica Day, Mrudula Joshi
Rheumatology. 2024-03-02

Press Mentions

FDA Extends Upadacitinib Indications to Children with ArthritisJune 5th, 2024
RINVOQ® (Upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic ArthritisJune 7th, 2024